Sorry, my frustration might be showing, but
"It’s also important to remember that remaining silent during the MHRA review is standard practice. When you’re in the middle of a first-in-class, process-defined, tissue-agnostic approval, regulators are setting precedent. Any misstep, even an innocently worded update, can cause delays by breaching confidentiality, creating inconsistencies between submissions and public statements, or signaling outcomes prematurely. That’s why companies go quiet until the decision is final."
I thought we were in labeling phase , so the "upsetting the MHRA decision" should be over with.
"This wait hasn’t been idle. In the background, they’ve expanded their patent portfolio, scaled manufacturing capacity, validated their method in academic settings, and aligned their operations with frameworks like SI 87 so approvals can cascade internationally. Every one of those steps has been done with the endgame in mind."
so why no PR about these things? They have nothing to do with the decision if dc-vax is approved or not.
"but price right now is about sentiment, not science or readiness."
right now its about communication.
"tissue-agnostic approval"
where is the evidence? Last I heard, they applied for treatment of 1 cancer.
" We’ve seen ample evidence that they’ve been working hard this entire time: building a regulatory framework, collaborating with top academic centers, securing ironclad IP, and establishing a manufacturing process that’s first in class."
if we have seen ample evidence, why hasn't the investing community seen it or reacted to it?
I have a colonoscopy on thursday. Might as well let the doctor ream me out along with an unamed company ...
I'd be interested in seeing what the dilution has been for the past few days.
AI
Market Data 
Markets 
